Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Best of ASCO® Miami 2017 /
Abiraterone for metastatic, hormone sensitive, prostate cancer

14th - 16th Jul 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.07.17
Views: 1356
Rating:

Prof Daniel Petrylak - Yale Cancer Center, New Haven, Connecticut, USA

Prof Petrylak talks with ecancer at the Best of ASCO 2017 meeting in Miami about the early use of the CYP17A1 inhibitor, abiraterone, for patients with metastatic, hormone sensitive, prostate cancer.

He goes on to discuss the data from, and the differences between, the STAMPEDE and LATITUDE trials.

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James discuss the latest in prostate cancer, in particular the STAMPEDE and LATITUDE trials here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation